Case series

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CR, Survival, CIS, FDA, Patient, Bladder cancer, Food, E pluribus unum, Treatment, Vol, Safety, The New England Journal of Medicine, Pivotal trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Literature, Immune system, NK, Massachusetts Medical Society, NEJM, Probability, Case series, PMID, Cystectomy, BCG, NMIBC, BLA, Exception, Vaccine, ImmunityBio COVID-19 vaccine, Tolerability

The BLA is supported by the results of ImmunityBio’s studies in bladder cancer including the pivotal QUILT-3.032 study (NCT03022825), published in NEJM Evidence1 in November 2022.

Key Points: 
  • The BLA is supported by the results of ImmunityBio’s studies in bladder cancer including the pivotal QUILT-3.032 study (NCT03022825), published in NEJM Evidence1 in November 2022.
  • Of the nine subjects, two were deceased from causes other than bladder cancer and one was lost to follow-up.
  • Final clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 with BCG in BCG-Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer (NMIBC).
  • Phase II/III Clinical Results of IL-15rαfc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma in Situ (CIS) Patients.

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

Retrieved on: 
Thursday, March 16, 2023
Anatomy, Surgeon, United Kingdom, Timmer, BRAVO, Risk, Infection, Case series, Hernia, Patient, S. Sivaraj, Capillary action through synthetic mesh, Biosynthesis, Consultant, Cohort (statistics), Publication, D. P, DOI, Use, Recurrence, Medical imaging, Dentistry, Victor Trotsyuk, Claessen

(NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.

Key Points: 
  • (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.
  • It is estimated that over two million hernia repairs will be performed this year within the United States, Europe, and the United Kingdom.
  • Launched in June 2016, OviTex has been rigorously studied in the clinical setting since its commercialization.
  • * Clinical Outcomes of Open Abdominal Wall Reconstruction with the Use of a Polypropylene Reinforced Tissue Matrix: A Multicenter Retrospective Study.

REGENATIVE LABS ANNOUNCES PUBLICATION OF GROUNDBREAKING PAPER ON WHARTON'S JELLY APPLICATIONS, OPENING THE DOOR FOR EXPANDED TREATMENT OF THE SI JOINT

Retrieved on: 
Thursday, March 9, 2023
Regenerative medicine, Cartilage, Pain management, Supplemental instruction, Case series, Research, Sacroiliac joint, Efficacy, Brace, Patient, Pain, Stiffness, Cryopreservation, Durability, Sacroiliac joint dysfunction, SI, WOMAC, Dentistry

Written by a team of translational experts, this paper provides a comprehensive analysis of the role of Wharton's Jelly applications in supplementing tissue issues within the refractory sacroiliac (SI) joint in 38 patients.

Key Points: 
  • Written by a team of translational experts, this paper provides a comprehensive analysis of the role of Wharton's Jelly applications in supplementing tissue issues within the refractory sacroiliac (SI) joint in 38 patients.
  • This data comes at an opportune time, as the current standard of care for SI joint pain only addresses the symptoms, using methods such as pain medication, braces, or SI fusion.
  • Statistically significant improvements in NPRS and WOMAC scores of the affected SI joint were reported after 90 days.
  • "We are delighted to see this important research published," said Tyler Barret, CEO of Regenative Labs.

Octave Presents Data from Nine Company and Partner Abstracts at ACTRIMS Forum 2023

Retrieved on: 
Saturday, February 25, 2023
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Radiology, Health, Pharmaceutical, Science, MIND, University of Michigan Institute for Social Research, DSM-IV codes, DO, Partnership, Treatment, Great America Committee, Patient, Biology, Abstract, Multiple sclerosis, Case series, Conference, MS, Poster, Proteomics, Medical imaging, Octave

Octave , a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of nine abstracts at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Conference 2023 .

Key Points: 
  • Octave , a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of nine abstracts at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Conference 2023 .
  • The abstracts, presented in partnership with several of Octave’s premier research partners, included data on the company’s MRI Insights program as well as applications of the company’s clinically-validated Multiple Sclerosis Disease Activity (MSDA) test, including real-world data as well as new deep scan proteomic approaches.
  • “We are thrilled to follow a very successful ECTRIMS meeting with an expanded body of research at this year’s ACTRIMS conference,” said William Hagstrom, Founder and Chief Executive Officer of Octave.
  • “This test can be used to verify stability and may support the clinical decision to alter therapy.

Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

Retrieved on: 
Wednesday, September 28, 2022
Biotechnology, Pharmaceutical, Health, Therapy, Drug discovery, FDA, CIO, IND, Case series, Patient, Pain management, CEO, Technology, NRT, COPD, Pharmaceutical industry, Asthma

Qnovia, Inc. (Qnovia), a pharma company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary diseases, today announced it has raised $17 million in Series A funding.

Key Points: 
  • Qnovia, Inc. (Qnovia), a pharma company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary diseases, today announced it has raised $17 million in Series A funding.
  • The financing was led by Blue Ledge Capital and included DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures.
  • Once the FDA approves our Investigational New Drug (IND) application, we plan to initiate a Phase 1 study for NRT in 2023.
  • As we pursue NRT authorization, we aim to identify significant expansion indications to pursue both alone and with partnerships.

Premia Spine’s TOPS™ Spinal Joint Replacement Shows Potential to Relieve Back Pain and Maintain Mobility Without Adjacent Level Degeneration

Retrieved on: 
Wednesday, September 7, 2022
Science, Neurology, Research, Surgery, Health, Medical Devices, Health Technology, Clinical Trials, Vertebral column, Vol, Spinal stenosis, CEO, Back pain, Rom, Pain, Spine, Lumbar spinal stenosis, TOPS, US Foods, Leg, Decompression, Food, Neurosurgery (journal), Multimedia, ASD, FDA, VAS, Gauge (instrument), Motion, ROM, Case series, Spondylolisthesis, Patient, Medical device, Bookbinding

View the full release here: https://www.businesswire.com/news/home/20220907005485/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220907005485/en/
    The TOPS System from Premia Spine.
  • The first and only facet joint replacement system for the lumbar spine, TOPS was developed to provide mobility, stability and durability after decompression for patients with lumbar spinal stenosis and degenerative spondylolisthesis.
  • Premia Spine, a medical technology company, aims to improve the lives of chronic leg and back pain patients with its TOPS System.
  • TOPS is designed to provide lasting mobility, stability and durability to patients with lumbar spinal stenosis, degenerative spondylolisthesis and related spinal conditions.

Lichen Planopilaris Responsive to a Natural Botanical Treatment

Retrieved on: 
Tuesday, June 21, 2022
American Academy, Department, Central centrifugal cicatricial alopecia, Irritation, Inflammation, Private practice, View, Hair, Faculty, LPP, University of California, Disease, University, Case series, Quality of life, Frustration, Itch, Patient, Multimedia, Woman, American Academy of Dermatology, Hair loss, Pharmaceutical industry, Medical device, Dermatology

LOS ANGELES, June 21, 2022 /PRNewswire/ -- Lichen Planopilaris (LPP) is a disease that can lead to patchy areas of permanent baldness.

Key Points: 
  • LOS ANGELES, June 21, 2022 /PRNewswire/ -- Lichen Planopilaris (LPP) is a disease that can lead to patchy areas of permanent baldness.
  • In a recent study titled: Lichen Planopilaris Responsive to a Novel Phytoactive Botanical Treatment: A Case Series , published in Dermatology and Therapy, four patients from two clinics with LPP successfully responded to a new botanical formula, either applied topically or combined with its capsule formulation, Dr.UGro Gashee.
  • Within weeks of initiating treatment, all patients experienced resolution of symptoms and inflammation with signs of hair regrowth sustained throughout follow-up.
  • According to Dr. Umar, botanical formulations may be an important treatment regimen given their potential effectiveness and favorable safety profile, particularly for chronic conditions that typically require continued treatments for several years.

Surgeon Presentations to Highlight RxSight® Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Tuesday, April 19, 2022
LDD, Society, Biometrics, ASCRS, Poster, Intraocular lens, NASDAQ, Visual acuity, Ultraviolet, GLOBE, Semipermeable membrane, Terminology, Surgeon, Technology, Case series, American Society of Cataract and Refractive Surgery, Cataract, EDT, LAL, Refractive surgery, IOL, Radial keratotomy, Level 1, Telescopic sight, Medical device, Risk management, Patient, MD

Descemet Membrane Endothelial Keratoplasty Combined with Implantation of Light Adjustable Lens.

Key Points: 
  • Descemet Membrane Endothelial Keratoplasty Combined with Implantation of Light Adjustable Lens.
  • Intraocular Lens Position of Light Adjustable Lens and Biometric Changes: 1-Year Follow-up.
  • Light Adjustable Intraocular Lens in Patients with Radial Keratotomy Undergoing Cataract Surgery: A Case Series.
  • The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.

CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19

Retrieved on: 
Tuesday, September 14, 2021
Rivaroxaban, National Heart, Lung, and Blood Institute, National, Liver disease, SOCOM, NIH, INT, United States Special Operations Command, Adult, HHS, The Act, Private Securities Litigation Reform Act, Judgement, DOAC, Annual report, COVID-19, Twitter, European Union, Case series, FDA, ECMO, Facebook, Ticagrelor, Air Force Materiel Command, Union, Blood, Adsorption, Lung, Trauma, Death, CE marking, Cytosorbents Corporation, Office of Inspector General, U.S. Department of Health and Human Services, Federal, SEC, Professional corporation, NHLBI, DARPA, Cytokine adsorbing column, Myoglobin, Cardiopulmonary bypass, Company, Risk, Army of the United States, Cytokine release syndrome, United, U.S. Department of Defense Strategy for Operating in Cyberspace, Manifest and latent functions and dysfunctions, Bilirubin, Pharmaceutical industry

2021

Key Points: 
  • 2021
    CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.
  • These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist.
  • CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure.
  • The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection.